Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133198
Status:
COMPLETED
Last Update Posted:
2013-11-08
First Post:
2005-08-22
Brief Title:
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome RLS
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel Group Clinical Trial Comparing Fixed Doses of 025 mg 050 mg and 075 mg Pramipexole Mirapex Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12 week clinical trial was conducted in the United States in order to compare pramipexole Mirapex versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None